Objective To observe the clinical effect of Yixuesheng Jiaonang combined with pegylated interferonα-2a（ PEG-IFNα-2a） and ribavirin on viral hepatitis C（ CHC）. Methods According to random number table

80 patients with CHC were divided into treatment group of 40 cases and control group of 40 cases. Both groups were given PEG-IFNα-2a（ 180 μg each time

subcutaneous injection

once a week） and ribavirin（ 300 mg each time

oral administration

three times a day） for 6 months. In the first 3 months

treatment group was added with Yixuesheng Jiaonang orally（ 1 g each time

3 times a day）. After treatment

both groups were followed up for 6months. Changes of patients’ serum Alanine amino transaminase（ ALT）

quantity of hepatitis C virus

neutrophil count

hemoglobin content and platelet count were observed before and after treatment. Patients’ percentage of biochemical and virological responses and incidence of myelosuppression were compared. Results There was no significant difference in virological responses between the two groups in the 3rd and 6th month of treatment and the 6th month of following up（ P > 0. 05）. There was also no significant difference in biochemical responses between the two groups in the 6th month of treatment and the 6th month of following up（ P > 0. 05）. In the 3rd and 6th month of treatment

the incidence of myelosuppression in treatment group was 35. 00% and 22. 50%

respectively

both of which were lower than that in control group（ 80. 00% and 60. 00%

P < 0. 01）. Conclusion Combined with Yixuesheng Jiaonang

the effect of myelosuppression of PEG-IFNα2a and ribavirin treating CHC is attenuated

but the antiviral effect is not improved.